The invention provides a neoantigen (amino acid sequences such as SEQ ID No1: QLMPFGSLL and SEQ ID No02: QLMPFSCLL) of an epidermal growth factor receptor fragment sequence representing drug resistance point mutation of a third-generation skin growth factor receptor inhibitor drug-resistant mutation neoantigen, EGFR inhibitor and a pharmaceutical composition containing the peptide or RNA and used for treating non-small cell lung cancer, and the series of antigen peptides have the effect of activating T cells, and can be used for treating non-small cell lung cancer. A novel immunotherapy method is provided for preventing drug resistance of the third-generation EGFR inhibitor and treating non-small cell lung cancer with EGFR mutation or EGFR-TKI drug resistance in combination with the third-generation EGFR inhibitor.
Third-generation skin growth factor receptor inhibitor drug-resistant mutation neoantigen and application thereof